The positive rate of IGF2BP2 was approximately 55% in gastric cancer patients who experienced relapse within 1 year after surgery, while it was approximately 17% in patients without recurrence within 3 years (Fig. 3G). Here, IGF2BP2 is linked to gastric cancer.